Identification of a broad sarbecovirus neutralizing antibody targeting a conserved epitope on the receptor-binding domain

Yanqun Wang,Zhaoyong Zhang,Minnan Yang,Xinyi Xiong,Qihong Yan,Lei Cao,Peilan Wei,Yuting Zhang,Lu Zhang,Kexin Lv,Jiantao Chen,Xuesong Liu,Xiaochu Zhao,Juxue Xiao,Shengnan Zhang,Airu Zhu,Mian Gan,Jingjun Zhang,Ruoxi Cai,Jianfen Zhuo,Yanjun Zhang,Haiyue Rao,Bin Qu,Yuanyuan Zhang,Lei Chen,Jun Dai,Linling Cheng,Qingtao Hu,Yaoqing Chen,Huibin Lv,Ray T Y So,Malik Peiris,Jingxian Zhao,Xiaoqing Liu,Chris Ka Pun Mok,Xiangxi Wang,Jincun Zhao,Ray T.Y. So

DOI: https://doi.org/10.1016/j.celrep.2023.113653

IF: 8.8

2024-01-05

Cell Reports

Abstract:Wang et al. identify a broad-spectrum neutralization antibody, 5817, against SARS-CoV-2 VOCs and SARS-CoV. The EM structure of mAb 5817 in complex with Omicron spike shows a highly conserved epitope, only existing at the RBD open state. mAb 5817 potently protects mice from SARS-CoV-2 and SARS-CoV infection in vivo.

cell biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to find antibodies that can broadly neutralize SARS - CoV - 2 and its variants (such as Omicron) as well as related coronaviruses. Specifically, the researchers hope to find a broad - spectrum neutralizing antibody that can target SARS - CoV - 2 variants (including variants of concern, VOCs), SARS - CoV, and related bat and pangolin viruses. This antibody needs to have the following characteristics: 1. **Broad - spectrum neutralizing ability**: It can maintain high - efficiency neutralizing activity in multiple SARS - CoV - 2 variants and related coronaviruses. 2. **Low mutation sensitivity**: It can still maintain the neutralizing effect even when the virus mutates. 3. **Potential therapeutic and preventive effects**: It can effectively protect mice from SARS - CoV - 2 and SARS - CoV infections. By screening the immune cells of COVID - 19 recovered patients, the researchers discovered an antibody named 5817, which has the above - mentioned characteristics. The 5817 antibody not only shows broad - spectrum neutralizing ability against various variants of SARS - CoV - 2 (including Omicron and its sub - variants), but also shows neutralizing activity against SARS - CoV, bat coronavirus RaTG13, pangolin coronavirus GD - 2019, and bat coronavirus WIV1. ### Main findings - **Binding epitope of 5817 antibody**: The 5817 antibody recognizes a conserved cryptic epitope on the RBD (receptor - binding domain), and this epitope only exists in the open state of the RBD. - **Competitive analysis**: The 5817 antibody does not compete with most RBD - targeted neutralizing antibodies, indicating that its binding epitope is different from these antibodies. - **Structural analysis**: The structure of the 5817 antibody - Omicron spike protein complex was resolved by cryo - EM (cryo - electron microscopy), revealing the detailed interaction between the 5817 antibody and the RBD. - **Protection effect**: The 5817 antibody shows a strong protective effect against SARS - CoV - 2 Beta, Delta, Omicron, and SARS - CoV in the mouse model. ### Significance This study reveals a highly conserved cryptic epitope that can be recognized by the broad - spectrum neutralizing antibody 5817. This finding is helpful for the development of universal vaccines and therapeutic antibodies against possible future SARS - CoV - 2 variants.

Identification of a broad sarbecovirus neutralizing antibody targeting a conserved epitope on the receptor-binding domain

Broadly neutralizing antibodies against sarbecoviruses generated by immunization of macaques with an AS03-adjuvanted COVID-19 vaccine

Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents

Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses

Broad sarbecovirus neutralization by combined memory B cell antibodies to ancestral SARS-CoV-2

Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2

Potent neutralization by a receptor binding domain monoclonal antibody with broad specificity for SARS-CoV-2 JN.1 and other variants

A broadly neutralizing antibody protects against SARS-CoV, pre-emergent bat CoVs, and SARS-CoV-2 variants in mice

A Monoclonal Antibody That Neutralizes SARS-CoV-2 Variants, SARS-CoV, and Other Sarbecoviruses

Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain

A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice

Biparatopic antibody BA7208/7125 effectively neutralizes SARS-CoV-2 variants including Omicron BA.1-BA.5

Potent and broadly neutralizing antibodies against sarbecoviruses elicited by single ancestral SARS-CoV-2 infection

Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals

Distinct In Vitro and In Vivo Neutralization Profiles of Monoclonal Antibodies Elicited by the Receptor Binding Domain of the Ancestral SARS‐CoV‐2

Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics

Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer

Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes

Characterization of a neutralizing antibody that recognizes a loop region adjacent to the receptor-binding interface of the SARS-CoV-2 spike receptor-binding domain

An antibody that neutralizes SARS-CoV-1 and SARS-CoV-2 by binding to a conserved spike epitope outside the receptor binding motif

Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody